Matthew Taylor analyst JEFFERIES

Currently out of the existing stock ratings of Matthew Taylor, 160 are a BUY (60.84%), 80 are a HOLD (30.42%), 23 are a SELL (8.75%).

Matthew Taylor

Work Performance Price Targets & Ratings Chart

Analyst Matthew Taylor, currently employed at JEFFERIES, carries an average stock price target met ratio of 61.25% that have a potential upside of 16% achieved within 150 days. Previously, Matthew Taylor worked at UBS, BARCLAYS.

Matthew Taylor’s has documented 517 price targets and ratings displayed on 37 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BSX, Boston Scientific Corp at 24-Jun-2026.

Wall Street Analyst Matthew Taylor

Analyst best performing recommendations are on TNDM (TANDEM DIABETES CARE).
The best stock recommendation documented was for TNDM (TANDEM DIABETES CARE) at 11/27/2018. The price target of $36 was fulfilled within 2 days with a profit of $2.71 (8.14%) receiving and performance score of 40.7.

Average potential price target upside

ABT Abbott Laboratories BAX Baxter International BDX Becton Dickinson and Company DXCM DexCom EW Edwards Lifesciences Corp GMED Globus Medical INMD InMode Ltd ISRG Intuitive Surgical MASI Masimo MDT Medtronic PLC NUVA NuVasive PHG Koninklijke Philips NV ADR TFX Teleflex UTRS Minerva Surgical VAR Varian Medical Systems LIVN LivaNova PLC PODD Insulet RMD ResMed IART Integra LifeSciences Holdings NVRO Nevro Corp TNDM Tandem Diabetes Care ZBH Zimmer Biomet Holdings SYK Stryker ATEC Alphatec Holdings BSX Boston Scientific Corp AXNX Axonics Modulation Technologies PEN Penumbra CNMD CONMED HRC Hill-Rom Holdings ESTA Establishment Labs Holdings SENS Senseonics Holdings SIBN Si-Bone VREX Varex Imaging Corp NARI Inari Medical  GEHC GE HealthCare Technologies RWLK Rewalk Robotics Ltd BFLY Butterfly Network

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 19-Sep-2024

$115

$20.88 (22.18%)

$115

17 days ago
(22-Jun-2026)

2/7 (28.57%)

$27.17 (30.93%)

143

Buy Since 02-Jun-2021

$131

$36.88 (39.18%)

$131

2 months 12 days ago
(27-Apr-2026)

9/21 (42.86%)

$38.2 (41.16%)

559

Buy Since 17-Dec-2018

$143

$48.88 (51.93%)

$144

2 months 19 days ago
(20-Apr-2026)

19/31 (61.29%)

$47 (48.96%)

495

Buy Since 18-Jul-2018

$120

$25.88 (27.50%)

$134

2 months 22 days ago
(17-Apr-2026)

10/18 (55.56%)

$23.19 (23.95%)

290

Buy Since 25-May-2021

$120

$25.88 (27.50%)

$150

2 months 22 days ago
(17-Apr-2026)

1/7 (14.29%)

$23.19 (23.95%)

194

Show more analysts

Please expand the browser size to see the chart

Which stock is Matthew Taylor is most bullish on?

Potential upside of $55.43 has been obtained for PEN (PENUMBRA)

Which stock is Matthew Taylor is most reserved on?

Potential downside of $21.86 has been obtained for BSX (BOSTON SCIENTIFIC CORP)

What Year was the first public recommendation made by Matthew Taylor?

On 2010

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?